Fig. 2From: Pretargeting for imaging and therapy in oncological nuclear medicinePET imaging of a patient with metastatic breast carcinoma. a Pretargeted immuno-PET performed using the TF2 anti-CEA bispecific antibody and the 68Ga-labelled IMP-288 peptide detects more lesions than FDG-PET (b)Back to article page